Radiotherapy Plus Total Androgen Block Versus Radiotherapy Plus LHRH Analog Monotherapy for Non-metastatic Prostate Cancer

Research output: Contribution to journalArticle

Abstract

BACKGROUND/AIM: Patients with locally advanced prostate cancer are generally treated with radiotherapy (RT) which can be combined with hormonal therapy. RT plus monotherapy with luteinizing hormone-releasing hormone (LHRH) analog triptorelin was compared to RT plus total androgen block (TAB).

PATIENTS AND METHODS: A retrospective study was carried out on patients with locally advanced prostate cancer comparing RT plus monotherapy versus RT plus TAB.

RESULTS: For overall survival, no differences between patients receiving RT with monotherapy and those treated with TAB were observed. A trend favoring use of TAB was found for progression-free survival. No differences in late gastrointestinal and genitourinary toxicities were reported.

CONCLUSION: This study suggests that monotherapy with LHRH is as effective as TAB, which is important in selecting appropriate treatment considering that TAB can have higher risks of adverse events and reduce the quality of life of patients.

Original languageEnglish
Pages (from-to)3139-3143
Number of pages5
JournalAnticancer Research
Volume38
Issue number5
DOIs
Publication statusPublished - May 2018

Fingerprint

Gonadotropin-Releasing Hormone
Androgens
Prostatic Neoplasms
Radiotherapy
Triptorelin Pamoate
Disease-Free Survival
Retrospective Studies
Quality of Life
Survival
Therapeutics

Keywords

  • Aged
  • Androgen Antagonists/therapeutic use
  • Antineoplastic Agents/therapeutic use
  • Antineoplastic Agents, Hormonal/therapeutic use
  • Combined Modality Therapy/methods
  • Disease-Free Survival
  • Gonadotropin-Releasing Hormone/analogs & derivatives
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Prostatic Neoplasms/drug therapy
  • Radiotherapy/methods
  • Retrospective Studies
  • Triptorelin Pamoate/therapeutic use

Cite this

@article{8bfd033b8ebf4b938d1f0f3271f39b81,
title = "Radiotherapy Plus Total Androgen Block Versus Radiotherapy Plus LHRH Analog Monotherapy for Non-metastatic Prostate Cancer",
abstract = "BACKGROUND/AIM: Patients with locally advanced prostate cancer are generally treated with radiotherapy (RT) which can be combined with hormonal therapy. RT plus monotherapy with luteinizing hormone-releasing hormone (LHRH) analog triptorelin was compared to RT plus total androgen block (TAB).PATIENTS AND METHODS: A retrospective study was carried out on patients with locally advanced prostate cancer comparing RT plus monotherapy versus RT plus TAB.RESULTS: For overall survival, no differences between patients receiving RT with monotherapy and those treated with TAB were observed. A trend favoring use of TAB was found for progression-free survival. No differences in late gastrointestinal and genitourinary toxicities were reported.CONCLUSION: This study suggests that monotherapy with LHRH is as effective as TAB, which is important in selecting appropriate treatment considering that TAB can have higher risks of adverse events and reduce the quality of life of patients.",
keywords = "Aged, Androgen Antagonists/therapeutic use, Antineoplastic Agents/therapeutic use, Antineoplastic Agents, Hormonal/therapeutic use, Combined Modality Therapy/methods, Disease-Free Survival, Gonadotropin-Releasing Hormone/analogs & derivatives, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Prostatic Neoplasms/drug therapy, Radiotherapy/methods, Retrospective Studies, Triptorelin Pamoate/therapeutic use",
author = "Giulia Marvaso and Anna Viola and Cristiana Fodor and Jereczek-Fossa, {Barbara A}",
note = "Copyright{\circledC} 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.",
year = "2018",
month = "5",
doi = "10.21873/anticanres.12576",
language = "English",
volume = "38",
pages = "3139--3143",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Radiotherapy Plus Total Androgen Block Versus Radiotherapy Plus LHRH Analog Monotherapy for Non-metastatic Prostate Cancer

AU - Marvaso, Giulia

AU - Viola, Anna

AU - Fodor, Cristiana

AU - Jereczek-Fossa, Barbara A

N1 - Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

PY - 2018/5

Y1 - 2018/5

N2 - BACKGROUND/AIM: Patients with locally advanced prostate cancer are generally treated with radiotherapy (RT) which can be combined with hormonal therapy. RT plus monotherapy with luteinizing hormone-releasing hormone (LHRH) analog triptorelin was compared to RT plus total androgen block (TAB).PATIENTS AND METHODS: A retrospective study was carried out on patients with locally advanced prostate cancer comparing RT plus monotherapy versus RT plus TAB.RESULTS: For overall survival, no differences between patients receiving RT with monotherapy and those treated with TAB were observed. A trend favoring use of TAB was found for progression-free survival. No differences in late gastrointestinal and genitourinary toxicities were reported.CONCLUSION: This study suggests that monotherapy with LHRH is as effective as TAB, which is important in selecting appropriate treatment considering that TAB can have higher risks of adverse events and reduce the quality of life of patients.

AB - BACKGROUND/AIM: Patients with locally advanced prostate cancer are generally treated with radiotherapy (RT) which can be combined with hormonal therapy. RT plus monotherapy with luteinizing hormone-releasing hormone (LHRH) analog triptorelin was compared to RT plus total androgen block (TAB).PATIENTS AND METHODS: A retrospective study was carried out on patients with locally advanced prostate cancer comparing RT plus monotherapy versus RT plus TAB.RESULTS: For overall survival, no differences between patients receiving RT with monotherapy and those treated with TAB were observed. A trend favoring use of TAB was found for progression-free survival. No differences in late gastrointestinal and genitourinary toxicities were reported.CONCLUSION: This study suggests that monotherapy with LHRH is as effective as TAB, which is important in selecting appropriate treatment considering that TAB can have higher risks of adverse events and reduce the quality of life of patients.

KW - Aged

KW - Androgen Antagonists/therapeutic use

KW - Antineoplastic Agents/therapeutic use

KW - Antineoplastic Agents, Hormonal/therapeutic use

KW - Combined Modality Therapy/methods

KW - Disease-Free Survival

KW - Gonadotropin-Releasing Hormone/analogs & derivatives

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Proportional Hazards Models

KW - Prostatic Neoplasms/drug therapy

KW - Radiotherapy/methods

KW - Retrospective Studies

KW - Triptorelin Pamoate/therapeutic use

U2 - 10.21873/anticanres.12576

DO - 10.21873/anticanres.12576

M3 - Article

C2 - 29715154

VL - 38

SP - 3139

EP - 3143

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -